The Intravenous Immunoglobulin (IVIg) Market is segmented according to application, end use, product type, source, and geography. Market Research Future reports that the market was estimated at USD 12.39 billion in 2024 and is expected to reach USD 18.99 billion by 2035, growing at a CAGR of 3.96% between 2025 and 2035.

By application, the market includes immunodeficiency disorders, neurological disorders, autoimmune disorders, and infectious diseases. Immunodeficiency disorders currently represent the largest application segment, with approximately 57% share. Autoimmune disorders are emerging as an important growth area as awareness and treatment options continue to expand.

By end use, hospitals dominate with approximately 63% share, while clinics, homecare settings, and pharmaceutical companies also contribute to market demand. By source, human plasma represents the leading segment with approximately 68% share, while recombinant techniques are gaining attention because of technological and safety advantages.

Major companies operating in the market include Grifols, CSL Behring, Octapharma, Kedrion, Baxter International, Takeda Pharmaceutical, LFB, Biotest AG, and ADMA Biologics.

North America currently leads the market, followed by Europe and other regions. Competitive strategies include production expansion, technological development, product innovation, strategic collaborations, and strengthening distribution networks. Increasing healthcare expenditure and demand for immunotherapy are expected to influence competition over the coming years.

Discover emerging opportunities with in-depth research reports:

Pharmacy Automation Market Size

Pharmacy Automation Market Share

Pharmacy Automation Market Trends

Pharmaceutical Quality Control Market Growth

Pharmaceutical Quality Control Market Demand